Comparative Pharmacology
Head-to-head clinical analysis: ALBAMYCIN versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBAMYCIN versus ZMAX.
ALBAMYCIN vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic